• Publications
  • Influence
NCCN Task Force Report: Oral chemotherapy.
Oral chemotherapy is emerging as a new option for well-selected patients who can manage potentially complex oral regimens and self-monitor for potential complications. If a choice between oral andExpand
  • 324
  • 28
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.
PURPOSE The purpose of this study was to assess the incidence, presenting characteristics, and treatment outcomes of Richter's syndrome (RS) and factors predicting response and survival. PATIENTSExpand
  • 202
  • 21
  • PDF
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
PURPOSE We investigated the risk factors and management of pleural effusion associated with dasatinib therapy for chronic myelogenous leukemia (CML) after failure of imatinib. PATIENTS AND METHODSExpand
  • 338
  • 20
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
Early results of the fludarabine, cyclophosphamide, and rituximab (FCR) regimen in 224 patients showed that it was highly active as initial therapy of chronic lymphocytic leukemia. In this report, weExpand
  • 659
  • 13
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
Clofarabine (2-chloro-2'-fluoro-deoxy-9-beta-D-arabinofuranosyladenine) is a second-generation nucleoside analog with activity in acute leukemias. As clofarabine is a potent inhibitor ofExpand
  • 210
  • 10
  • PDF
Update on therapy of chronic lymphocytic leukemia.
There have been tremendous advances in the treatment of chronic lymphocytic leukemia (CLL) over the past decade, with the goal of therapy no longer being just to palliate symptoms but now to achieveExpand
  • 113
  • 7
  • PDF
NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.
The advent of imatinib has dramatically improved outcomes in patients with chronic myelogenous leukemia (CML). It has become the standard of care for all patients with newly diagnosed chronic-phaseExpand
  • 47
  • 5
  • PDF
Treatment of Chronic Myelogenous Leukemia: Current Status and Investigational Options
VER THE PAST few years, several important studies 0 related to the treatment of Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) have matured. These include single andExpand
  • 197
  • 4
  • PDF
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
The aim of this study was to evaluate the activity of topotecan in patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). Forty-seven patients with a diagnosis ofExpand
  • 124
  • 3
  • PDF
Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance.
The BCR-ABL chromosomal translocation is a central event in the pathogenesis of chronic myelogenous leukemia (CML). One of the ABL1 promoters (Pa) and the coding region of the gene are usuallyExpand
  • 69
  • 3